Concepts (296)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nicotine | 88 | 2020 | 179 | 20.170 |
Why?
|
| Smoking Cessation | 44 | 2020 | 216 | 9.960 |
Why?
|
| Smoking | 47 | 2020 | 544 | 9.740 |
Why?
|
| Tobacco Use Disorder | 40 | 2020 | 90 | 7.380 |
Why?
|
| Substance Withdrawal Syndrome | 15 | 2018 | 76 | 3.010 |
Why?
|
| Conditioning, Operant | 23 | 2017 | 125 | 2.510 |
Why?
|
| Nicotinic Agonists | 16 | 2019 | 40 | 2.260 |
Why?
|
| Double-Blind Method | 20 | 2020 | 597 | 1.720 |
Why?
|
| Tobacco | 7 | 2018 | 58 | 1.680 |
Why?
|
| Male | 88 | 2020 | 20763 | 1.570 |
Why?
|
| Adult | 50 | 2020 | 10048 | 1.540 |
Why?
|
| Humans | 88 | 2020 | 34594 | 1.460 |
Why?
|
| Self Administration | 36 | 2020 | 386 | 1.380 |
Why?
|
| Motivation | 11 | 2020 | 123 | 1.360 |
Why?
|
| Dose-Response Relationship, Drug | 31 | 2020 | 755 | 1.340 |
Why?
|
| Choice Behavior | 5 | 2016 | 88 | 1.290 |
Why?
|
| Female | 56 | 2020 | 21553 | 1.120 |
Why?
|
| Rats | 34 | 2020 | 1946 | 1.080 |
Why?
|
| Public Health | 6 | 2020 | 94 | 1.060 |
Why?
|
| Young Adult | 21 | 2020 | 2837 | 1.050 |
Why?
|
| Patient Compliance | 5 | 2018 | 218 | 1.040 |
Why?
|
| Alcohol Drinking | 4 | 2016 | 261 | 1.030 |
Why?
|
| Rats, Sprague-Dawley | 29 | 2020 | 923 | 0.990 |
Why?
|
| Middle Aged | 30 | 2020 | 12735 | 0.980 |
Why?
|
| Cotinine | 8 | 2021 | 52 | 0.980 |
Why?
|
| Reward | 6 | 2015 | 70 | 0.950 |
Why?
|
| Inhalation Exposure | 2 | 2016 | 10 | 0.940 |
Why?
|
| Tobacco Industry | 3 | 2014 | 25 | 0.890 |
Why?
|
| Cocaine | 5 | 2014 | 355 | 0.880 |
Why?
|
| Weight Gain | 4 | 2018 | 117 | 0.840 |
Why?
|
| Mental Disorders | 3 | 2020 | 127 | 0.810 |
Why?
|
| Government Regulation | 4 | 2016 | 32 | 0.810 |
Why?
|
| Animals | 42 | 2020 | 8579 | 0.810 |
Why?
|
| Cues | 10 | 2014 | 65 | 0.800 |
Why?
|
| Volatile Organic Compounds | 2 | 2020 | 9 | 0.770 |
Why?
|
| Health Policy | 4 | 2016 | 96 | 0.720 |
Why?
|
| Reinforcement Schedule | 11 | 2015 | 103 | 0.690 |
Why?
|
| Adolescent | 18 | 2020 | 3807 | 0.670 |
Why?
|
| Marijuana Smoking | 2 | 2020 | 39 | 0.640 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2019 | 568 | 0.630 |
Why?
|
| Nitrosamines | 1 | 2019 | 11 | 0.610 |
Why?
|
| Discrimination Learning | 2 | 2016 | 20 | 0.600 |
Why?
|
| Depression | 2 | 2016 | 458 | 0.600 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2019 | 365 | 0.580 |
Why?
|
| Monoamine Oxidase Inhibitors | 2 | 2016 | 4 | 0.580 |
Why?
|
| Alkaloids | 2 | 2016 | 9 | 0.580 |
Why?
|
| Commerce | 2 | 2016 | 70 | 0.570 |
Why?
|
| Behavior, Animal | 7 | 2016 | 303 | 0.560 |
Why?
|
| Photic Stimulation | 8 | 2012 | 172 | 0.550 |
Why?
|
| United States | 14 | 2020 | 4283 | 0.550 |
Why?
|
| Behavior | 2 | 2015 | 31 | 0.530 |
Why?
|
| Product Labeling | 1 | 2017 | 19 | 0.530 |
Why?
|
| Eating | 4 | 2018 | 81 | 0.510 |
Why?
|
| Risk-Taking | 1 | 2017 | 99 | 0.510 |
Why?
|
| Models, Theoretical | 1 | 2018 | 146 | 0.500 |
Why?
|
| Tranylcypromine | 2 | 2016 | 2 | 0.490 |
Why?
|
| Harm Reduction | 1 | 2016 | 16 | 0.490 |
Why?
|
| Body Weight | 4 | 2018 | 343 | 0.480 |
Why?
|
| Sucrose | 3 | 2020 | 20 | 0.480 |
Why?
|
| Disease Models, Animal | 9 | 2020 | 1129 | 0.470 |
Why?
|
| Neostriatum | 1 | 2015 | 29 | 0.470 |
Why?
|
| Cocaine-Related Disorders | 3 | 2009 | 125 | 0.460 |
Why?
|
| Acetaldehyde | 1 | 2015 | 4 | 0.460 |
Why?
|
| Quinoxalines | 2 | 2014 | 13 | 0.460 |
Why?
|
| Carbolines | 1 | 2015 | 6 | 0.460 |
Why?
|
| Benzazepines | 2 | 2014 | 25 | 0.460 |
Why?
|
| Behavior, Addictive | 6 | 2020 | 40 | 0.450 |
Why?
|
| Heart Rate | 4 | 2012 | 372 | 0.440 |
Why?
|
| Biomedical Research | 1 | 2016 | 186 | 0.430 |
Why?
|
| Conditioning, Classical | 1 | 2014 | 30 | 0.420 |
Why?
|
| Task Performance and Analysis | 1 | 2014 | 54 | 0.420 |
Why?
|
| Learning | 1 | 2015 | 88 | 0.420 |
Why?
|
| Methadone | 2 | 2005 | 12 | 0.420 |
Why?
|
| Token Economy | 1 | 2013 | 3 | 0.410 |
Why?
|
| Saccades | 1 | 2014 | 25 | 0.410 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 4 | 2008 | 26 | 0.410 |
Why?
|
| Caudate Nucleus | 1 | 2013 | 29 | 0.400 |
Why?
|
| Self Efficacy | 3 | 2008 | 79 | 0.400 |
Why?
|
| Opioid-Related Disorders | 2 | 2005 | 69 | 0.380 |
Why?
|
| Animal Experimentation | 1 | 2012 | 6 | 0.380 |
Why?
|
| Health Behavior | 1 | 2014 | 246 | 0.380 |
Why?
|
| Blood Pressure | 4 | 2012 | 902 | 0.380 |
Why?
|
| Decision Making | 1 | 2014 | 203 | 0.360 |
Why?
|
| Analgesics, Opioid | 2 | 2005 | 265 | 0.350 |
Why?
|
| Aged | 10 | 2020 | 11023 | 0.330 |
Why?
|
| United States Food and Drug Administration | 3 | 2015 | 53 | 0.320 |
Why?
|
| Analysis of Variance | 6 | 2017 | 508 | 0.300 |
Why?
|
| Brain | 2 | 2014 | 1032 | 0.290 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2016 | 1393 | 0.290 |
Why?
|
| Acetylcysteine | 2 | 2019 | 11 | 0.290 |
Why?
|
| Receptors, Nicotinic | 3 | 2007 | 62 | 0.280 |
Why?
|
| Phobic Disorders | 1 | 2008 | 10 | 0.270 |
Why?
|
| Time Factors | 8 | 2016 | 2353 | 0.270 |
Why?
|
| Carbon Monoxide | 3 | 2020 | 10 | 0.260 |
Why?
|
| Personal Satisfaction | 1 | 2007 | 28 | 0.250 |
Why?
|
| Creatinine | 2 | 2018 | 206 | 0.250 |
Why?
|
| Schizophrenia | 2 | 2020 | 32 | 0.250 |
Why?
|
| Linear Models | 3 | 2019 | 465 | 0.240 |
Why?
|
| Substance-Related Disorders | 2 | 2006 | 142 | 0.240 |
Why?
|
| Association Learning | 7 | 2016 | 14 | 0.230 |
Why?
|
| Ganglionic Stimulants | 4 | 2016 | 7 | 0.230 |
Why?
|
| Comorbidity | 4 | 2015 | 596 | 0.230 |
Why?
|
| Central Nervous System Stimulants | 1 | 2006 | 85 | 0.220 |
Why?
|
| Substance Abuse, Intravenous | 2 | 2009 | 30 | 0.210 |
Why?
|
| Oxygen | 2 | 2016 | 152 | 0.210 |
Why?
|
| Infusions, Intravenous | 7 | 2016 | 110 | 0.210 |
Why?
|
| Neural Pathways | 2 | 2016 | 116 | 0.200 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2016 | 260 | 0.200 |
Why?
|
| Prefrontal Cortex | 2 | 2014 | 90 | 0.200 |
Why?
|
| Affect | 3 | 2009 | 72 | 0.190 |
Why?
|
| Prevalence | 4 | 2016 | 1034 | 0.190 |
Why?
|
| Causality | 4 | 2019 | 38 | 0.190 |
Why?
|
| Nicotinic Antagonists | 4 | 2012 | 17 | 0.190 |
Why?
|
| Dinoprost | 2 | 2019 | 11 | 0.190 |
Why?
|
| Heroin | 1 | 2002 | 33 | 0.180 |
Why?
|
| Random Allocation | 2 | 2013 | 257 | 0.180 |
Why?
|
| Adolescent Behavior | 2 | 2016 | 64 | 0.170 |
Why?
|
| Oxidative Stress | 2 | 2019 | 265 | 0.160 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2021 | 44 | 0.160 |
Why?
|
| Feedback | 1 | 2020 | 42 | 0.160 |
Why?
|
| Terpenes | 1 | 2020 | 7 | 0.160 |
Why?
|
| Methylazoxymethanol Acetate | 1 | 2020 | 1 | 0.160 |
Why?
|
| Mouth | 1 | 2020 | 24 | 0.160 |
Why?
|
| Saliva | 2 | 2017 | 41 | 0.160 |
Why?
|
| Carcinogens | 1 | 2019 | 41 | 0.150 |
Why?
|
| Dinoprostone | 1 | 2019 | 37 | 0.150 |
Why?
|
| Eicosanoids | 1 | 2019 | 9 | 0.150 |
Why?
|
| Hazardous Substances | 1 | 2019 | 2 | 0.150 |
Why?
|
| Bupropion | 2 | 2009 | 7 | 0.140 |
Why?
|
| Marketing | 1 | 2019 | 41 | 0.140 |
Why?
|
| Phenanthrenes | 1 | 2018 | 3 | 0.140 |
Why?
|
| Inflammation | 2 | 2019 | 557 | 0.140 |
Why?
|
| Breath Tests | 1 | 2018 | 18 | 0.140 |
Why?
|
| Public Policy | 1 | 2018 | 34 | 0.140 |
Why?
|
| Mecamylamine | 4 | 2012 | 11 | 0.140 |
Why?
|
| Smoke | 1 | 2018 | 16 | 0.140 |
Why?
|
| Individuality | 2 | 2015 | 10 | 0.140 |
Why?
|
| Recurrence | 3 | 2015 | 296 | 0.140 |
Why?
|
| Obesity | 2 | 2017 | 1246 | 0.140 |
Why?
|
| Health Education | 1 | 2019 | 170 | 0.140 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2016 | 96 | 0.140 |
Why?
|
| Area Under Curve | 1 | 2018 | 98 | 0.140 |
Why?
|
| C-Reactive Protein | 1 | 2019 | 248 | 0.140 |
Why?
|
| Feeding Behavior | 3 | 2018 | 168 | 0.140 |
Why?
|
| Food | 2 | 2016 | 49 | 0.140 |
Why?
|
| Pyridines | 2 | 2016 | 87 | 0.130 |
Why?
|
| Drug Administration Schedule | 4 | 2007 | 306 | 0.130 |
Why?
|
| Terminology as Topic | 1 | 2017 | 71 | 0.130 |
Why?
|
| Lipid Metabolism | 1 | 2018 | 113 | 0.130 |
Why?
|
| Glucuronosyltransferase | 1 | 2017 | 5 | 0.130 |
Why?
|
| Dopamine Uptake Inhibitors | 2 | 2009 | 147 | 0.130 |
Why?
|
| Patient Dropouts | 1 | 2017 | 28 | 0.130 |
Why?
|
| Psychopharmacology | 1 | 2016 | 3 | 0.130 |
Why?
|
| New Zealand | 1 | 2016 | 6 | 0.130 |
Why?
|
| Extinction, Psychological | 4 | 2009 | 17 | 0.130 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2016 | 5 | 0.120 |
Why?
|
| History, 21st Century | 1 | 2016 | 63 | 0.120 |
Why?
|
| History, 20th Century | 1 | 2016 | 76 | 0.120 |
Why?
|
| World Health Organization | 1 | 2016 | 17 | 0.120 |
Why?
|
| Lithium Chloride | 1 | 2016 | 3 | 0.120 |
Why?
|
| Severity of Illness Index | 3 | 2008 | 922 | 0.120 |
Why?
|
| Anabasine | 1 | 2016 | 1 | 0.120 |
Why?
|
| Rest | 1 | 2016 | 53 | 0.120 |
Why?
|
| Age Factors | 1 | 2019 | 1262 | 0.120 |
Why?
|
| Tars | 1 | 2015 | 3 | 0.120 |
Why?
|
| Attitude | 2 | 2020 | 43 | 0.120 |
Why?
|
| Tobacco Use Cessation | 1 | 2015 | 22 | 0.110 |
Why?
|
| Research Design | 1 | 2017 | 337 | 0.110 |
Why?
|
| Brain Mapping | 1 | 2016 | 208 | 0.110 |
Why?
|
| Genetic Variation | 2 | 2017 | 254 | 0.110 |
Why?
|
| Impulsive Behavior | 2 | 2012 | 8 | 0.110 |
Why?
|
| Cross-Sectional Studies | 3 | 2008 | 1608 | 0.110 |
Why?
|
| Injections, Subcutaneous | 2 | 2012 | 37 | 0.110 |
Why?
|
| Parietal Lobe | 1 | 2014 | 17 | 0.110 |
Why?
|
| Gyrus Cinguli | 1 | 2014 | 27 | 0.100 |
Why?
|
| Frontal Lobe | 1 | 2014 | 41 | 0.100 |
Why?
|
| Follow-Up Studies | 3 | 2016 | 2367 | 0.100 |
Why?
|
| Statistics as Topic | 1 | 2013 | 111 | 0.100 |
Why?
|
| Health Promotion | 1 | 2015 | 265 | 0.100 |
Why?
|
| Rodentia | 1 | 2012 | 10 | 0.090 |
Why?
|
| Demography | 1 | 2012 | 112 | 0.090 |
Why?
|
| Social Environment | 3 | 2009 | 82 | 0.090 |
Why?
|
| Alcoholism | 2 | 2010 | 104 | 0.090 |
Why?
|
| Risk Factors | 3 | 2008 | 4137 | 0.090 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2012 | 82 | 0.090 |
Why?
|
| Students | 3 | 2008 | 178 | 0.080 |
Why?
|
| Regression Analysis | 2 | 2008 | 310 | 0.080 |
Why?
|
| Pilot Projects | 1 | 2012 | 586 | 0.080 |
Why?
|
| Emotions | 2 | 2020 | 60 | 0.080 |
Why?
|
| Age of Onset | 1 | 2009 | 95 | 0.080 |
Why?
|
| Administration, Cutaneous | 1 | 2009 | 119 | 0.070 |
Why?
|
| Naltrexone | 1 | 2008 | 23 | 0.070 |
Why?
|
| Child | 3 | 2010 | 2615 | 0.070 |
Why?
|
| Narcotic Antagonists | 1 | 2008 | 47 | 0.070 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2007 | 29 | 0.070 |
Why?
|
| Risk Assessment | 2 | 2015 | 1508 | 0.070 |
Why?
|
| Mental Health | 1 | 2008 | 126 | 0.060 |
Why?
|
| Ethnic Groups | 1 | 2009 | 483 | 0.060 |
Why?
|
| Probability | 1 | 2007 | 168 | 0.060 |
Why?
|
| Behavioral Research | 1 | 2006 | 4 | 0.060 |
Why?
|
| Acetylcholine | 1 | 2006 | 69 | 0.060 |
Why?
|
| Health Surveys | 1 | 2007 | 202 | 0.060 |
Why?
|
| Phenotype | 3 | 2017 | 657 | 0.060 |
Why?
|
| Guidelines as Topic | 1 | 2006 | 51 | 0.060 |
Why?
|
| Sleep | 1 | 2007 | 90 | 0.060 |
Why?
|
| Risk | 1 | 2007 | 325 | 0.060 |
Why?
|
| Injections, Intravenous | 1 | 2006 | 102 | 0.060 |
Why?
|
| Heroin Dependence | 1 | 2005 | 8 | 0.060 |
Why?
|
| Psychometrics | 2 | 2021 | 143 | 0.060 |
Why?
|
| Aging | 1 | 2012 | 1010 | 0.060 |
Why?
|
| Models, Animal | 2 | 2016 | 198 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 542 | 0.060 |
Why?
|
| Protein Binding | 1 | 2004 | 255 | 0.050 |
Why?
|
| Arousal | 1 | 2003 | 20 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2003 | 100 | 0.050 |
Why?
|
| Lighting | 1 | 2002 | 5 | 0.050 |
Why?
|
| Wisconsin | 1 | 2021 | 21 | 0.040 |
Why?
|
| Minnesota | 1 | 2020 | 20 | 0.040 |
Why?
|
| Fatigue | 1 | 2020 | 90 | 0.040 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2020 | 11 | 0.040 |
Why?
|
| Hospitalization | 1 | 2003 | 500 | 0.040 |
Why?
|
| Sampling Studies | 1 | 2019 | 45 | 0.040 |
Why?
|
| Erythrocyte Indices | 1 | 2019 | 4 | 0.040 |
Why?
|
| Erythrocyte Count | 1 | 2019 | 4 | 0.040 |
Why?
|
| Animals, Newborn | 1 | 2020 | 143 | 0.040 |
Why?
|
| Platelet Count | 1 | 2019 | 25 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2020 | 201 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2019 | 50 | 0.040 |
Why?
|
| F2-Isoprostanes | 1 | 2019 | 20 | 0.040 |
Why?
|
| Acrylonitrile | 1 | 2019 | 1 | 0.040 |
Why?
|
| Acrolein | 1 | 2019 | 4 | 0.040 |
Why?
|
| Toxicology | 1 | 2019 | 5 | 0.040 |
Why?
|
| Metabolome | 1 | 2019 | 40 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2019 | 85 | 0.040 |
Why?
|
| Calorimetry | 1 | 2018 | 3 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2020 | 926 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 2 | 2007 | 51 | 0.030 |
Why?
|
| Glucuronides | 1 | 2017 | 2 | 0.030 |
Why?
|
| Philadelphia | 1 | 2017 | 6 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2017 | 63 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 804 | 0.030 |
Why?
|
| Urinalysis | 1 | 2016 | 27 | 0.030 |
Why?
|
| Universities | 2 | 2008 | 152 | 0.030 |
Why?
|
| Dietary Fats | 1 | 2017 | 115 | 0.030 |
Why?
|
| Monoamine Oxidase | 1 | 2016 | 6 | 0.030 |
Why?
|
| Infusions, Parenteral | 1 | 2016 | 69 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2016 | 60 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2016 | 97 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2016 | 63 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2019 | 954 | 0.030 |
Why?
|
| Corpus Striatum | 1 | 2016 | 75 | 0.030 |
Why?
|
| Visual Perception | 2 | 2007 | 122 | 0.030 |
Why?
|
| Genotype | 1 | 2017 | 744 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2008 | 823 | 0.030 |
Why?
|
| Dangerous Behavior | 1 | 2014 | 4 | 0.030 |
Why?
|
| European Continental Ancestry Group | 1 | 2017 | 1176 | 0.020 |
Why?
|
| Research | 1 | 2012 | 88 | 0.020 |
Why?
|
| Basal Ganglia | 1 | 2012 | 23 | 0.020 |
Why?
|
| Continental Population Groups | 1 | 2012 | 245 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2012 | 189 | 0.020 |
Why?
|
| African Americans | 1 | 2017 | 1435 | 0.020 |
Why?
|
| Prazosin | 1 | 2009 | 12 | 0.020 |
Why?
|
| Skin Temperature | 1 | 2009 | 17 | 0.020 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2009 | 36 | 0.020 |
Why?
|
| Exploratory Behavior | 1 | 2009 | 34 | 0.020 |
Why?
|
| Safety | 1 | 2009 | 82 | 0.020 |
Why?
|
| Personal Autonomy | 1 | 2008 | 9 | 0.020 |
Why?
|
| Filtration | 1 | 2008 | 3 | 0.020 |
Why?
|
| Logistic Models | 1 | 2010 | 808 | 0.020 |
Why?
|
| Administration, Inhalation | 1 | 2008 | 56 | 0.020 |
Why?
|
| Social Perception | 1 | 2008 | 25 | 0.020 |
Why?
|
| Water | 1 | 2008 | 70 | 0.020 |
Why?
|
| Reference Values | 1 | 2008 | 265 | 0.020 |
Why?
|
| Patient Selection | 1 | 2009 | 291 | 0.020 |
Why?
|
| Thiazoles | 1 | 2007 | 36 | 0.020 |
Why?
|
| Dihydro-beta-Erythroidine | 1 | 2007 | 1 | 0.020 |
Why?
|
| Aconitine | 1 | 2007 | 5 | 0.020 |
Why?
|
| Infusion Pumps | 1 | 2007 | 9 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2008 | 193 | 0.020 |
Why?
|
| Brain Chemistry | 1 | 2006 | 46 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2014 | 3623 | 0.020 |
Why?
|
| Species Specificity | 1 | 2006 | 101 | 0.020 |
Why?
|
| Child of Impaired Parents | 1 | 2006 | 3 | 0.020 |
Why?
|
| Fathers | 1 | 2006 | 13 | 0.020 |
Why?
|
| Marijuana Abuse | 1 | 2006 | 20 | 0.020 |
Why?
|
| Remission Induction | 1 | 2006 | 97 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2006 | 372 | 0.010 |
Why?
|
| Psychomotor Performance | 1 | 2005 | 116 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2009 | 657 | 0.010 |
Why?
|
| Sex Factors | 1 | 2006 | 708 | 0.010 |
Why?
|
| Models, Biological | 1 | 2006 | 432 | 0.010 |
Why?
|
| Disease Progression | 1 | 2006 | 634 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2006 | 939 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2005 | 182 | 0.010 |
Why?
|
| Environment | 1 | 2002 | 51 | 0.010 |
Why?
|
| Environment, Controlled | 1 | 2002 | 3 | 0.010 |
Why?
|